论文部分内容阅读
目的 :观察苯那普利和氯沙坦联合应用对早期糖尿病肾病的保护作用。方法 :将 62例 2型糖尿病肾病患者随机分为三组 ,分别使用苯那普利、氯沙坦及两药联用治疗 18周 ,观察治疗前后各组患者的平均动脉压 (MAP)、尿白蛋白排泄率 (UAER)、内生肌酐清除率 (CCr)、尿素氮 (BUN)、空腹血糖 (FBG)、糖化血红蛋白 (HbA1C)、血脂变化。结果 :联合或单用苯那普利和氯沙坦治疗早期DN ,均有明显降低血压、UAER和BUN的作用 ,各组在治疗前后具有明显差异 (P <0 0 0 1或P <0 0 5 ) ;但联合用药组效果更好 ,尤其是联合用药组降低UAER作用与同期两单用组比较 ,具有明显差异 (P <0 0 5 ) ;各组FBG、CH、TG治疗前后及治疗后各组间比较无统计学意义 (P >0 0 5 )。结论 :苯那普利和氯沙坦联合应用治疗早期糖尿病肾病更合理、更有效。
Objective: To observe the protective effect of benazepril combined with losartan on early diabetic nephropathy. Methods: Sixty-two patients with type 2 diabetic nephropathy were randomly divided into three groups: benazepril, losartan and the combination of two drugs for 18 weeks respectively. Mean arterial pressure (MAP) and urine Albumin excretion rate (UAER), creatinine clearance rate (CCr), blood urea nitrogen (BUN), fasting blood glucose (FBG), glycosylated hemoglobin (HbA1C), blood lipid changes. Results: Both benazepril and losartan combined with or without early treatment of DN significantly decreased the blood pressure, UAER and BUN, and there was significant difference between before and after treatment (P <0.01 or P <0.05) (P <0.05). However, the effect of combination therapy group was better, especially the effect of reducing UAER in combination group was significantly different from that in the two groups at the same period (P <0.05). Before and after FBG, CH and TG treatment There was no significant difference between the two groups (P> 0.05). Conclusion: The combination of benazepril and losartan in the treatment of early diabetic nephropathy is more reasonable and effective.